Asset Details
Do you wish to reserve the book?
Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment
Do you wish to request the book?
Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment
2025
Overview
Abstract
Context
Teprotumumab, which targets the insulin-like growth factor-1 receptor, is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease (TED).
Objective
This study aimed to identify potential safety signals of teprotumumab by analyzing postmarketing safety data from the FDA Adverse Event Reporting System (FAERS) database in 2023.
Methods
The case/noncase approach was used to estimate the reporting odds ratio (ROR) and information component (IC) with relevant 95% CI for adverse events (AEs) that numbered 3 or more.
Results
A total of 2158 cases were included in the analysis. Main safety signals identified were ear and labyrinth disorders, reproductive system and breast disorders, metabolism and nutrition disorders, and gastrointestinal disorders. Specifically, autophony (ROR [95% CI] = 4188.34 [1403.29-12500.8]), eyelid retraction (ROR [95% CI] = 2094.17 [850.69-5155.29]), permanent deafness (ROR [95% CI] = 1552.35 [789.07-3053.98]), bilateral deafness (ROR [95% CI] = 73.12 [41.14-129.97]), inflammatory bowel disease (ROR [95% CI] = 23.26 [13.46-40.19]), hyperglycemic hyperosmolar nonketotic syndrome (ROR [95% CI] = 17.75 [5.70-55.28]), and amenorrhea (ROR [95% CI] = 47.98 [36.22-63.54]) showed significant safety signals with teprotumumab.
Conclusion
This study identified ear and labyrinth disorders, and reproductive system and breast disorders, as specific safety signals of teprotumumab. Clinicians and pharmacists should be vigilant regarding these AEs. However, available data are currently insufficient, and further pharmacovigilance and surveillance are needed to fully understand this issue.
Publisher
Oxford University Press
Subject
/ Adult
/ Adverse Drug Reaction Reporting Systems - statistics & numerical data
/ Aged
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Breast
/ Clinical
/ Complications and side effects
/ Deafness
/ Ear
/ Eyelid
/ Female
/ Graves Ophthalmopathy - chemically induced
/ Graves Ophthalmopathy - drug therapy
/ Humans
/ Insulin-like growth factor I
/ Male
/ Product Surveillance, Postmarketing - statistics & numerical data
/ Safety
